Genmab A/S (NASDAQ:GMAB) Reaches New 52-Week High – Should You Buy?

Posted by George Bondi on Oct 7th, 2026

Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) shares reached a new 52-week high during mid-day trading on Monday. The stock traded as high as $36.07 and last traded at $35.6350, with a volume of 2153207 shares changing hands. The stock had previously closed at $34.75.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

Positive Sentiment: Genmab and partner AbbVie reported that the Phase 3 EPCORE DLBCL-2 trial met its progression-free survival objective. Epkinly combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed DLBCL patients. The companies plan to discuss the results with global regulators, creating a potential path toward a major label expansion. AbbVie and Genmab announce positive EPCORE DLBCL-2 results
Positive Sentiment: The data position Epkinly as a potentially strong competitor in the T-cell engager market. Analysts noted that the treatment effect may compare favorably with Roche’s Polivy in a similar setting and could support upside to Genmab’s $3 billion-plus peak-sales outlook. Genmab Epkinly shines in Phase 3 DLBCL trial
Positive Sentiment: Recent coverage highlighted above-average trading volume, positive earnings-estimate revisions and a move toward the stock’s 52-week high, suggesting investor momentum has increased following the trial announcement. Strength seen in Genmab
Neutral Sentiment: Genmab reported a 45.9% response rate for Rina-S in an ovarian-cancer study. While the result adds support for the pipeline, the market reaction was less favorable than for the Epkinly data, indicating investors may need more information on durability and comparative efficacy. Genmab reports Rina-S results

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Genmab A/S in a research note on Monday, September 14th. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and raised their price target for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. Finally, Guggenheim boosted their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $40.83.

View Our Latest Report on GMAB

Genmab A/S Price Performance

The stock has a fifty day moving average of $33.13 and a 200 day moving average of $29.15. The stock has a market cap of $23.59 billion, a price-to-earnings ratio of 29.76, a P/E/G ratio of 2.09 and a beta of 0.81. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44.

Genmab A/S (NASDAQ:GMAB – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. On average, analysts expect that Genmab A/S Sponsored ADR will post 1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership increased its position in shares of Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after buying an additional 1,334,919 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after buying an additional 1,126,069 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares in the last quarter. SummitTX Capital L.P. purchased a new position in shares of Genmab A/S during the 1st quarter valued at approximately $2,263,000. Finally, Ishara Investments LP acquired a new stake in Genmab A/S in the 4th quarter valued at $2,156,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

(Get Free Report)

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.